

Resource Summary Report

Generated by [dkNET](#) on Sep 11, 2026

RenCa

RRID:CVCL_2174

Type: Cell Line

Proper Citation

BCRJ Cat# 0346, RRID:CVCL_2174

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2174

Proper Citation: BCRJ Cat# 0346, RRID:CVCL_2174

Description: Cell line RenCa is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Male

Disease: Mouse kidney carcinoma

Defining Citation: [PMID:3486710](#), [PMID:31220119](#)

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: RenCa

Synonyms: Renca, RENCA, Renal Carcinoma

Cross References: ATCC:CRL-2947, BCRJ:0346, BioGRID_ORCS_Cell_line:1259, BioSample:SAMN11397652, CCRID:6101MOU-CERC000110, ChEMBL-Cells:ChEMBL3307979, ChEMBL-Targets:ChEMBL612568, CLS:400321, KCLB:80022, PubChem_Cell_line:CVCL_2174, Wikidata:Q54949734

ID: CVCL_2174

Vendor: BCRJ

Catalog Number: 0346

Record Creation Time: 20220427T221455+0000

Record Last Update: 20260905T182208+0000

Ratings and Alerts

No rating or validation information has been found for RenCa.

No alerts have been found for RenCa.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 52 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Li Y, et al. (2026) Tumor-Intrinsic ARHGEF3 Enhances Antitumor Immunity by Promoting T-Cell Infiltration and Limiting Myeloid Cell-Mediated Immunosuppression. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(38), e23895.

Gruber DR, et al. (2026) Targeted Delivery of a Potent STING Agonist Payload via an Antibody-Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models. Molecular cancer therapeutics, 25(3), 457.

Wang J, et al. (2026) Tumor-Resident Streptococcus pneumoniae Promotes Malignant Progression and Pazopanib Resistance in Clear Cell Renal Cell Carcinoma. Cancer research, 86(9), 2237.

Djureinovic D, et al. (2026) CD40 agonism in renal cell carcinoma enhances immune checkpoint activity through myeloid cells. iScience, 29(7), 116527.

Wu L, et al. (2026) ICAM1high Neutrophils Sculpt Tumor Evolution and Metastasis through Symbiotic Adhesion and Reverse Migration. Cancer research.

Mogi M, et al. (2026) Pan-cancer analysis of RNA expression signatures associated with cancer tissue architecture. British journal of cancer, 134(1), 141.

Liu X, et al. (2026) High throughput screening identifies sanguinarine chloride as a multifaceted therapeutic agent for PRCC-TFE3 rRCC by targeting lactylation-driven VEGFB-VEGFR2 signaling and PMN-MDSC infiltration. Journal of advanced research.

Liu Y, et al. (2026) Mitofusin-2 suppresses tumor immune escape through EGFR/STAT3-mediated PD-L1 transcription. Cell death & disease, 17(1).

Yamauchi T, et al. (2026) Valine availability controls oncogenic cell-cycle progression through translation of D-type cyclins. Biochemical pharmacology, 246, 117706.

Emanuelli A, et al. (2025) Targeting the IL34-CSF1R axis improves metastatic renal cell carcinoma therapy outcome via immune-vascular crosstalk regulation. iScience, 28(6), 112752.

Gong L, et al. (2025) Cancer immunology data engine reveals secreted AOAH as a potential immunotherapy. *Cell*, 188(18), 5062.

Xu JY, et al. (2025) Intestinal Lachnospiraceae bacterium-derived propionate inhibits the progression of clear cell renal cell carcinoma. *Cell reports. Medicine*, 6(10), 102410.

Braun LM, et al. (2025) Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. *Cancer cell*, 43(2), 269.

Cook AL, et al. (2025) Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape. *eLife*, 13.

Shi J, et al. (2025) SPP1+ Neutrophils Mediate Resistance to Immune Checkpoint Blockade in BAP1-Inactivated Tumors. *Cancer research*, 85(22), 4433.

Fan Y, et al. (2025) Itaconate transporter SLC13A3 confers immunotherapy resistance via alkylation-mediated stabilization of PD-L1. *Cell metabolism*, 37(2), 514.

Abdelhamed S, et al. (2025) PF-08046032: A Novel, Investigational CD25-Directed Antibody-Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors. *Molecular cancer therapeutics*, 24(7), 963.

Yoshida Y, et al. (2025) Targeting macrophage circadian rhythms with microcurrent stimulation to activate cancer immunity through phagocytic defense. *Theranostics*, 15(2), 340.

Zhang Q, et al. (2025) The extracellular-matrix-remodeling capability exposes therapeutic vulnerability in a subset of renal cell carcinomas with tumor thrombi. *Developmental cell*.

Xu S, et al. (2024) Development of a PAK4-targeting PROTAC for renal carcinoma therapy: concurrent inhibition of cancer cell proliferation and enhancement of immune cell response. *EBioMedicine*, 104, 105162.